Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine

• Published in: Biological psychiatry (1969) 2018-01, Vol.83 (1), p.29-37
• Main Authors: Ghosal, Sriparna, Bang, Eunyoung, Yue, Wenzhu, Hare, Brendan D., Lepack, Ashley E., Girgenti, Matthew J., Duman, Ronald S.
• Format: Article
• Language: English
• Subjects: Animals; Antidepressive Agents - pharmacology; Brain - drug effects; Brain - metabolism; Brain - pathology; Brain-Derived Neurotrophic Factor - genetics; Brain-Derived Neurotrophic Factor - metabolism; Calcium Channels, L-Type - metabolism; Cells, Cultured; Depression; Depressive Disorder - drug therapy; Depressive Disorder - metabolism; Depressive Disorder - pathology; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases - metabolism; gamma-Aminobutyric Acid - metabolism; Male; Mice, Transgenic; Motor Activity - drug effects; mTORC1; Muscarinic receptor; Neurons - drug effects; Neurons - metabolism; Neurons - pathology; Prefrontal cortex; Rats, Sprague-Dawley; Receptor, Muscarinic M1 - antagonists & inhibitors; Receptor, Muscarinic M1 - metabolism; Receptor, trkB - metabolism; Scopolamine - pharmacology; Synaptosomes - drug effects; Synaptosomes - metabolism; Time Factors; TrkB receptor; Verapamil - pharmacology; Voltage-dependent calcium channel
• ISSN: 0006-3223; 1873-2402
• DOI: 10.1016/j.biopsych.2017.06.017

Brain-derived neurotrophic factor (BDNF) plays a key role in the pathophysiology and treatment of depression. Recent clinical studies demonstrate that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces rapid antidepressant effects in patients with depression. Rodent studies demonstrate that scopolamine increases glutamate transmission and synaptogenesis in the medial prefrontal cortex (mPFC). Here we tested the hypothesis that activity-dependent BDNF release within the mPFC is necessary for the antidepressant actions of scopolamine. Behavioral effects of scopolamine were assessed in BDNF Val/Met knock-in mice, in which BDNF processing and release are impaired. In addition, intra-mPFC infusion of a BDNF-neutralizing antibody was performed to test the necessity of BDNF release in driving scopolamine-induced behavioral responses. Further in vivo and in vitro experiments were performed to delineate BDNF-dependent mechanisms underlying the effects of scopolamine. We found that BDNF Met/Met mice have attenuated responses to scopolamine and that anti-BDNF antibody infusions into the mPFC prevented the antidepressant-like behavioral effects of scopolamine. In vitro experiments show that scopolamine rapidly stimulates BDNF release and tropomyosin receptor kinase B–extracellular signal-regulated kinase signaling. Moreover, these effects require alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor activation and are blocked by neuronal silencing. Importantly, pretreatment with verapamil prevented scopolamine-induced behavioral responses and BDNF–tropomyosin receptor kinase B signaling, suggesting that these effects are dependent on activation of voltage-dependent calcium channels. The results identify an essential role for activity-dependent BDNF release in the rapid antidepressant effects of scopolamine. Attenuation of responses in BDNF Met mice indicates that patients with the Met allele may be less responsive to scopolamine.